A considerable increase in the risk of developing cardiovascular disease is conveyed not only by inflammation, but also by the use of glucocorticoids to treat inflammation. In this Viewpoint, the authors discuss the challenge of balancing the relative benefits and hazards of glucocorticoid treatment for inflammatory diseases, as well as the tantalizing prospect of identifying subgroups of the population at risk for cardiovascular disease.
- Frank Buttgereit
- Gerd-Rüdiger Burmester
- Brian J Lipworth
